Merck (MRK) is reportedly planning to double the production of molnupiravir, an antiviral COVID pill, next year. The Financial Times reported the drugmaker has secured deals to provide COVID ...

Ridgeback and Merck have partnered to develop molnupiravir and will share profits. In some of the children Denison treats as the director of pediatric infectious diseases at VUMC, remdesivir ...

The US government has placed an order with Merck & Co to buy 1.7 million courses of its antiviral therapy molnupiravir for COVID-19, assuming it gets approved for use by the FDA. The $1.2 billion ...

The EMA has started a rolling review of Merck & Co and Ridgeback Biotherapeutics' much-anticipated oral antiviral molnupiravir as a treatment for COVID-19 in adults. Molnupiravir is already filed ...

While Merck's oral drug Molnupiravir has already been cleared by the United Kingdom to treat COVID-19, a Paraguayan laboratory has filed for its emergency registration in the South American ...

The new anti-viral drug brought out by Merck Pharmaceuticals, Molnupiravir, seems to be a promising development in the global fight against COVID-19. Early results from the phase-3 trial of the ...

Merck's drug was far less effective in a late ... The FDA said on Thursday that molnupiravir is not recommended for pregnant people. "As a woman of child-bearing age, I don't think I would want ...

Molnupiravir was developed by Merck, Sharp and Dohme and Ridgeback Biotherapeutics. Merck explained that in clinical trials, Molnupiravir was administered to 775 patients who had recently been ...

The government agreed last month to pay Merck and its partner Ridgeback Biotherapeutics about $1.2 billion for 1.6 million courses of their drug molnupiravir. In addition, Kishida announced last ...

Merck agrees to allow Sinopharm to sell molnupiravir COVID drug in China The drugmaker said in a statement that it reached a cooperation framework agreement with Sinopharm that grants the Chinese ...